Pyridoxine in Preventing Hand-Foot Syndrome Caused by Capecitabine in Patients With Cancer

Overview

RATIONALE: Pyridoxine may help prevent hand-foot syndrome caused by capecitabine in patients with cancer. It is not yet known whether pyridoxine is more effective than a placebo in preventing hand-foot syndrome in patients with cancer. PURPOSE: This randomized phase III trial is studying pyridoxine to see how well it works compared with a placebo in preventing hand-foot syndrome caused by capecitabine in patients with cancer.

Full Title of Study: “Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: August 2014

Detailed Description

OBJECTIVES: Primary – Compare the incidence of capecitabine-induced palmar-plantar erythrodysesthesia (hand-foot syndrome [HFS]) ≥ grade 2 in patients with cancer treated with pyridoxine hydrochloride vs placebo. Secondary – Compare the time to onset of HFS ≥ grade 2 in patients treated with these regimens. – Compare the quality of life changes in patients treated with these regimens. – Identify factors predicting toxicity from capecitabine chemotherapy. OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to gender and treatment setting (adjuvant/neoadjuvant vs palliative setting). Patients are randomized to 1 of 2 treatment arms. – Arm I: Beginning concurrently with planned capecitabine treatment, patients receive oral pyridoxine hydrochloride once daily on days 1-21. – Arm II: Beginning concurrently with planned capecitabine treatment, patients receive oral placebo once daily on days 1-21. In both arms, treatment repeats every 21 days for up to 8 courses (until discontinuation of capecitabine treatment). Quality of life is assessed at baseline, at the beginning of courses 2, 4, 6, and 8, and at the end of the study.

Interventions

  • Dietary Supplement: pyridoxine hydrochloride
    • Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
  • Other: Placebo

Arms, Groups and Cohorts

  • Active Comparator: Pyridoxine hydrochloride
    • Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
  • Placebo Comparator: Placebo
    • Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle

Clinical Trial Outcome Measures

Primary Measures

  • First incidence of hand-foot syndrome (HFS) ≥ grade 2 according to NCI CTCAE vs 3.0
    • Time Frame: up to 8 cycles

Secondary Measures

  • Time to the onset of HFS ≥ grade 2
    • Time Frame: days to weeks
  • Quality of life as measured by EuroQOL (EQ-5D) questionnaire
    • Time Frame: QOL assessment at baseline, at beginning of cycles 2, 4, 6, 8 and at the end of the study.

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Diagnosis of cancer – Must be receiving single-agent capecitabine either in the adjuvant/neoadjuvant or palliative setting at a dose of ≥ 1000 mg/m² twice daily on days 1-14 (given in 3-week courses) PATIENT CHARACTERISTICS: – Life expectancy > 12 weeks – No preexisting neuropathy – No known allergy to pyridoxine hydrochloride and its incipients – No other dermatologic condition that, in the opinion of the physician, may affect the hands or feet or may complicate evaluation during study treatment PRIOR CONCURRENT THERAPY: – See Disease Characteristics – No prior capecitabine – Concurrent radiotherapy, steroids, and/or biological therapy (e.g., trastuzumab [Herceptin®] or bevacizumab) allowed provided they do not cause hand-foot syndrome (HFS) – No other concurrent drugs (e.g., docetaxel or doxorubicin hydrochloride liposome) that can cause HFS – No concurrent drugs (e.g., oxaliplatin or taxanes) that can cause neuropathy – No concurrent pyridoxine hydrochloride-containing preparations (e.g., multivitamins or vitamin B complex) – No concurrent over-the-counter products that contain urea or lactic acid – No concurrent drugs reported to have drug interactions with pyridoxine hydrochloride (e.g., cycloserine; hydralazine; immunosuppressants; isoniazid; levodopa; estrogen or estrogen-containing contraceptives; penicillamine; phenobarbitone; phenytoin; or pyrazinamide)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Cancer Centre, Singapore
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yoon-Sim Yap, FRACP, MBBS, Principal Investigator, National Cancer Centre, Singapore

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.